Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Concordia Healthcare Corp. T.CXR.R

Healthcare Biotechnology


TSX:CXR.R - Post by User

Concordia Healthcare Corp. > Testing
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Comment by TraderBenon Dec 22, 2016 4:11pm
142 Views
Post# 25637308

RE:RE:Testing

RE:RE:TestingBroke $2.14 and closed below support. Bearish trend will continue without positive news.


Americanbulls
$CXRX the bear pattern is confirmed & a SHORT signal is issued @ americanbulls.com/SignalPag... . Short Level: 2.28 Target: 0.92



TraderBen wrote:

Longs want CXRX to close above $2.14 for or will test next support at 2.01

Winter, keep your rage off the bullboard. Its not true about putting your shares up for sale.

But keep your 300 shares if it makes you feel better. Noone wants them, Baggie.


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities